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Background: The emergence of KPC-producing K. pneumoniae has now become a global concern. KPC beta-
lactamases are plasmid-borne and, like extended spectrum beta lactamases (ESBLs), can accumulate and transfer
resistance determinants to other classes of antibiotics. Therefore, infection control guidelines on early identification
and control of the spread of organisms carrying these resistant determinants are needed.
Findings: Klebsiella pneumoniae carbapenemase (KPC) was detected in two isolates of carbapenem-resistant K.
pneumoniae obtained from patients at an Italian teaching hospital. The first strain was isolated from a culture
drawn from a central venous device (CVC) in a patient with Crohn’s disease who was admitted to a
gastroenterology ward. The second was isolated from a urine sample collected from an indwelling urinary catheter
in an intensive care unit (ICU) patient with a subdural haematoma. The patients had not travelled abroad. Both
isolates were resistant to all b-lactams and were susceptible to imipenem and meropenem but resistant to
ertapenem. Isolates also showed resistance to other classes of non-b-lactam antibiotics, such as quinolones,
aminoglycosides (with the exception for amikacin), trimethoprim-sulfamethoxazole (TMP-SMX) and nitrofurantoin.
They were determined to contain the plasmid encoding the carbapenemase gene bla-KPC and were also positive
in the Hodge test.
Conclusions: This is the second report of KPC-producing isolates in Italy, but the first concerning KPC type 2 gene,
and it may have important implications for controlling the transmission of microorganisms resistant to antibiotics.
Findings
Klebsiella pneumoniae carbapenemase (KPC) is a mole-
cular class A serine b-lactamase belonging to functional
group 2f [1]. KPC was first reported in 2001 after its
discovery in a K. pneumoniae clinical isolate collected in
North Carolina during the ICARE (Intensive Care Anti-
microbial Resistance Epidemiology) surveillance study
[1-3]. The first detection of KPC-2 on a plasmid in
P. aeruginosa was reported; this represents a disturbing
development in the spread of these carbapenemases
[2,4]. Although the KPC b-lactamases are predominantly
found in K. pneumoniae, there have been reports of
these enzymes in Enterobacter spp. and in Salmonella
spp and in other genera of the Enterobacteriaceae family
[5-10].
KPC-positive strains are typically resistant to the peni-
cillins, extended-spectrum cephalosporins, and aztreo-
nam, but the MICs of these drugs and of the
carbapenems are reduced in the presence of clavulanic
acid due to enzyme inhibition [2]. Isolates that acquire
this enzyme are usually resistant to several other classes
of antimicrobial agents used as treatment options.
Laboratory identification of KPC-producing clinical iso-
lates will be critical for limiting the spread of this resis-
tance mechanism. The failure of automated susceptibility
testing systems to detect KPC-mediated resistance was
previously noted, particularly if ertapenem, which was
determined to be more susceptible to the idrolytic activity
of KPC carbanemase, was not tested [11]. After the rapid
expansion of the KPC class of carbapenemases along
the east coast of the United States, reports from across
the world began to appear. A report from France in
2005 documented KPC-2 in a K. pneumoniae strain from
a patient who had been in New York for medical
* Correspondence: carla.fontana@uniroma2.it
1Department of Experimental Medicine and Biochemical Sciences, “Tor
Vergata” University of Rome - Via Montpellier 1, Rome, 00133, Italy
Fontana et al. BMC Research Notes 2010, 3:40
http://www.biomedcentral.com/1756-0500/3/40
© 2010 Fontana et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.treatment [12]. KPC-producing organisms have continued
to spread over time and have now been reported in 27
states in the United States and in many countries around
the world, including China, Colombia, Brazil, Israel,
Canada, France, the Republic of Ireland, Greece (where
infection caused by KPC is mainly due to hyperepidemic
clone) and more recently in Italy [8-19]. We report, in
this paper, the first two cases of KPC2 producing K.
pneumoniae in Italy. Our finding confirms that KPC pro-
ducing isolates are a global concern and that every effort
should be made from the laboratory to early identifica-
tion of these phenotypes.
Case Presentation
Case 1
A 48-year-old man was admitted to Tor Vergata Univer-
sity hospital in February 2009). He had suffered from
Crohn’s disease since 1990, with prolonged illness
exacerbation periods. He received numerous treatments
and had recently decided to treat himself with steroids.
A colonoscopy was performed to remove a colic polyp,
but an intra-abdominal perforation complicated the
exam. A stercoraceous peritonitis developed and the
patient urgently underwent intestinal resection and sple-
nectomy. Seven days later, an ileal necrosis of the
colostomy tract appeared and he underwent a resection
of ileum. A few days later, he developed a fever and leu-
cocitosis, and a Computed Tomography (CT) scan
revealed an abdominal abscess that was drained. Differ-
ent bacterial isolates were obtained from the blood and
abscess drainage cultures (Enterococcus faecalis, Escheri-
chia coli, Candida albicans, Klebsiella pneumoniae and
Acineobacter baumannii), K. pneumoniae was cultured
f r o mt h et i po faC V C( w h i c hw a sc o n f i r m e da sK P C
producing in two days). Numerous antibiotic treatments
were used. The initial drug regimen consisted of linezo-
lid, amikacin, caspofungin, piperacillin-tazobactam,
metronidazole and then, after the identification of a
KPC-producing K. pneumoniae (due to the positivity of
the Hodge’s test), the antibiotic therapy was shifted to
an association of tigecycline (100 mg for the first dose
and then 50 mg every 12 h) and amikacin (1 g once a
day) for 9 days. At the time of multi-drug resistant A.
baumannii isolation, amikacin was suspended and tige-
cycline continued in combination with colistin
(2.000.000 units every 8 h). The association of tigecy-
cline and colistin was suspended after 16 days. The
patient was discharged without fever, abdominal drai-
nage was removed when nothing further was picked up.
Case 2
A 79-year-old woman with an intra-cerebral haemor-
rhage was admitted to the neurosurgical department of
Tor Vergata University hospital in March, 2009. She
had lost consciousness following a sudden headache and
subsequent head trauma. The patient was operated on
immediately and was later admitted to the ICU. Her
past history revealed chronic atrial fibrillation, so she
was administered dicumarol. Moreover, in the past she
had suffered from recurrent urinary tract infections trea-
ted by her family doctor with ciprofloxacin. On admis-
sion, the patient was intubated and a urinary catheter
was inserted, a central intravenous catheter was placed
in her subclavian vein, and an arterial line was also
inserted. She started a course of therapy with piperacil-
lin/tazobactam (4.5 g/i.v. q6h) for the treatment of
aspiration pneumonia due to P. aeruginosa.O nt h e
ninth day, the patient’s temperature increased to 39°C
and she experienced chills. Her white blood count and
C reactive protein also increased (11.300 mm
3 and
102 mg/L, respectively). Several blood cultures (from the
CVC or from the peripheral vein), urine and bronchial
secretions (BAS) were collected for cultures. An empiri-
cal treatment was started by adding teicoplanin (600 mg
i.v. q24 h) and levofloxacin (500 mg i.v. q12h) to the
previous antibiotic therapy. The blood cultures from the
CVC resulted positive for Proteus mirabilis and Entero-
coccus faecalis. The culture of BAS evidenced the same
P. aeruginosa previously isolated, while the culture of
urines yielded 10
6 CFU/mL of K. pneumoniae KPC-pro-
ducing (initially confirmed by the Hodge’s test). The
previous antibiotic treatment was altered to amikacin
(1,5 g i.v. q24h), while teicoplanin was maintained at the
same dose. In the meantime, CVC was removed. After
eight days, there was a second episode of fever. The
amikacin treatment was interrupted and a tigecycline
regimen was initiated (100 mg for the first dose and
then 50 mg q12h). Blood and urine samples were col-
lected again and a single blood culture was positive for
P. aeruginosa. After ten days of treatment with merope-
nem, the infectious event clinically resolved, but the
patient’s conditions slowly worsened. After 27 days of
hospitalization, the patient died due to the progression
of her brain damage.
Methods
Isolates were tested for susceptibility using Vitek2 (bio-
M é r i e u x ,D u r h a m ,N C ) ,u s i n gA S TG N 1 3a n dA S T
GN074, as well as the AST N022 card. Susceptibility
was also confirmed for meropenem, imipenem, ertape-
nem, colistin and amikacin using Etest (bioMérieux
Italia; Firenze, Italy) according to the manufacturer’s
recommendations and incubated for 18 hours at 35°C in
ambient air. MICs were interpreted according to the
Clinical Laboratory Standards Institute (CLSI) guidelines
[20]. MIC for colistin were interpreted according to the
EUCAST breakpoints available at the web site http://
www.srga.org/eucastwt/MICTAB/index.html. Isolates
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exclude the possibility of a metallo-beta-lactamases
(MBL) production a synergy test using imipenem and
EDTA discs was used, the test was performed according
to CLSI [20,22]
Analysis of b-lactamase genes (including blaKPC
blaTEM blaOXA,a n dblaSHV), CTX-M type, VIM type,
IMP type as well as blaAmpC were preformed as pre-
viously reported [13,23-26].
Amplified products of the expected size were con-
firmed as KPC by sequencing. For typing of the blaKPC
gene, overlapping PCR reactions were performed using
the following primer pairs: F-5’CGGAACCATTC-
GCTAAACTC3’ and R-3’GGCGGCGTTATCACTG-
TATT5’ primers; F-5’CGCCGTGCAATACAGTGATA3’
and R-3’CGTTGACGCCCAATCC5’ primers [13].
Amplification products were purified using the Mon-
tage PCR Centrifugal Filter Device (Millipore Corpora-
tion, Billerica, MA), and sequencing was performed by
Big Dye Terminators V1.1 (Applied Biosystems, Foster
City, CA) and migrated with an automated sequencer
(ABI Prism 310; Applied Biosystems). Sequences were
aligned and compared using the National Center for
Biotechnology Information database http://www.ncbi.
nlm.nih.gov/.
Results
Isolates from case 1 and case 2 were both multi-drug
resistant, being resistant to all b-lactam, quinoloni and
aminoglycosides (with the exception of amikacin), TMP-
SMX, and nitrofurantoin, and were susceptible to tigecy-
cline and colistin (see Table 1). The behaviour versus
carbapenemic compounds was typical for KPC isolates:
both isolates were susceptible to imipenem (MIC =
1 μg/L) and meropenem (MIC = 2 μg/L) and resistant
to ertapenem (MIC = 8 μg/L). Screening with ertape-
nem indicated the possibility of a KPC, which was con-
firmed by the modified Hodge test. While the MBL test
was negative. Analysis of b-lactamase genes by PCR and
sequencing revealed the presence of blaKPC-2, and
blaSHV-1, while genes encoding other enzymes bla-
TEM, blaOXA, CTX-M type, VIM type, IMP type as
well as blaAmpC were not detected.
Both patients improved clinically with tigecycline
treatment, even if for the second patient a septic event
due to P. aeruginosa (successive to K. pneumoniae infec-
tions) needed to be treated with meropenem.
Conclusion
This is the second documented appearance of a class A
carbapenemase-producing isolate of K. pneumoniae in
Italy, harbouring KPC type 2 gene, that was not asso-
ciated with travel abroad. KPC b-lactamases (KPC 1-7)
confer decreased susceptibility or resistance to all b-lac-
tams [14,27]. The isolate showed reduced susceptibility
or resistance to four different antibiotics, limiting the
therapeutic options to polymixin, amikacin, and tigecy-
cline [13]. At present, these are the second published
cases of KPC-producing K. pneumoniae infections in
Italy, after that published by Giani et al [19]. The disse-
mination of KPC-producing organisms is no longer
restricted to the United States and has emerged as a
global concern, aided by the recently described mobile
genetic element Tn 4401, which carries the KPC genes
[28]. Carbapenemase-producing pathogens cause infec-
tions that are difficult to treat and have high mortality
rates due to their appearance in multidrug-resistant
pathogens such as K. pneumoniae, P. aeruginosa,a n d
Acinetobacter spp [2]. The first descriptions of these
enzymes as species-specific chromosomal carbapene-
m a s e sh a v em o r er e c e n t l yb e e nf o l l o w e db yt h ea p p e a r -
ance of carbapenemase genes that are easily transferred
on mobile elements between species. While considered
by some to be relatively rare, reports of their occurrence
in outbreak settings have steadily increased [2,13,14].
Detecting their entry into the hospital environment is
the first step that clinical microbiologists can take to
address this problem. Care in detection is needed,
because high carbapenem MICs are not always evident
and the phenotype could be confused with that
described by Cagnacci et al [11,22,29]. Therefore, it is
essential that the initial complete screening of the isolate
includes Hodge’s test as well as MBL test. Evaluation of
effective antibiotic options and rigorous infection con-
trol measures will help in the fight against carbapene-
mase-producing organisms [2]. Regardless of the
geographic location, microbiology laboratories in Italy
need to ensure that they have methods in place for the
accurate detection of KPC-producing organisms and
must constantly be aware of their potential to spread.
Table 1 Susceptibility of KPC-producing Klebsiella pneumoniae isolates
MICs (μg/ml)
Isolates AMP AMC PIP PTZ CAZ CTX FEP IPM MEM EPT AMK CIP TGC CS TMP-SMX NT
Case 1 isolate 32 32 128 128 16 64 16 1 2 8 2 8 0.5 0.5 320 512
Case 2 isolate 32 32 128 128 16 64 16 1 2 8 2 8 0.5 0.5 320 512
Abbreviations: AMP, ampicillin, AMC, amoxicillin-clavulanate; PIP, piperacillin, PTZ, piperacillin-tazobactam; CAZ, ceftazidime; CTX, cefotaxime, FEP, cefepime; IPM,
imipenem; MEM, meropenem; EPT, ertapenem; AMK, amikacin; CIP, ciprofloxacin; TGC, tigecycline; CS, colistin; TMP-SMX, trimethoprim-sulfamethoxazole; NT,
nitrofurantoin.
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